First year real life experience with tenofovir alafenamide fumarate: The pythagorean cohort.
Hepatitis B
real life
tenofovir alafenamide
Journal
Hepatology forum
ISSN: 2757-7392
Titre abrégé: Hepatol Forum
Pays: Turkey
ID NLM: 9918351171306676
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
received:
17
11
2022
revised:
05
02
2023
accepted:
03
04
2023
medline:
30
5
2023
pubmed:
30
5
2023
entrez:
30
5
2023
Statut:
epublish
Résumé
In chronic hepatitis B infection, antiviral therapy significantly reduces the incidence of complications. This study aimed to present real-life 12-month effectiveness and safety data for TAF. This Pythagoras Retrospective Cohort Study included patients from 14 centers in Turkiye. The study presents 12-month results of 480 patients treated with TAF as initial therapy or after switching from another antiviral drug. The study shows treatment of about 78.1% patients with at least one antiviral agent (90.6% tenofovir disoproxil [TDF]). The rate of undetectable HBV DNA increased in both treatment-experienced and naive patients. In TDF-experienced patients, the rate of alanine transaminase (ALT) normalization increased slightly (1.6%) within 12 months, but the change was not statistically significant (p=0.766). Younger age, low albumin, and high body mass index and cholesterol were identified as risk factors for abnormal ALT after 12 months, but no linear relationship was detected. In TDF-experienced patients, renal and bone function indicators showed significant improvement three months after the transition to TAF and remained stable for 12 months. Real-life data demonstrated effective virological and biochemical responses with TAF therapy. After switching to TAF treatment, gains in kidney and bone functions were achieved in the early period.
Sections du résumé
Background and Aim
UNASSIGNED
In chronic hepatitis B infection, antiviral therapy significantly reduces the incidence of complications. This study aimed to present real-life 12-month effectiveness and safety data for TAF.
Materials and Methods
UNASSIGNED
This Pythagoras Retrospective Cohort Study included patients from 14 centers in Turkiye. The study presents 12-month results of 480 patients treated with TAF as initial therapy or after switching from another antiviral drug.
Results
UNASSIGNED
The study shows treatment of about 78.1% patients with at least one antiviral agent (90.6% tenofovir disoproxil [TDF]). The rate of undetectable HBV DNA increased in both treatment-experienced and naive patients. In TDF-experienced patients, the rate of alanine transaminase (ALT) normalization increased slightly (1.6%) within 12 months, but the change was not statistically significant (p=0.766). Younger age, low albumin, and high body mass index and cholesterol were identified as risk factors for abnormal ALT after 12 months, but no linear relationship was detected. In TDF-experienced patients, renal and bone function indicators showed significant improvement three months after the transition to TAF and remained stable for 12 months.
Conclusion
UNASSIGNED
Real-life data demonstrated effective virological and biochemical responses with TAF therapy. After switching to TAF treatment, gains in kidney and bone functions were achieved in the early period.
Identifiants
pubmed: 37250926
doi: 10.14744/hf.2022.2022.0043
pii: hf-4-061
pmc: PMC10209973
doi:
Types de publication
Journal Article
Langues
eng
Pagination
61-68Informations de copyright
© Copyright 2023 by Hepatology Forum.
Déclaration de conflit d'intérêts
The authors have no conflict of interest to declare.
Références
Lancet Gastroenterol Hepatol. 2020 May;5(5):441-453
pubmed: 32087795
Ther Adv Infect Dis. 2021 Feb 5;8:2049936120985954
pubmed: 33614029
J Viral Hepat. 2021 Jun;28(6):942-950
pubmed: 33749086
Lancet Gastroenterol Hepatol. 2016 Nov;1(3):185-195
pubmed: 28404091
Antivir Ther. 2010;15(2):227-33
pubmed: 20386078
J Infect Dis. 2015 Feb 1;211(3):374-82
pubmed: 25156561
Clin Infect Dis. 2015 Aug 1;61(3):403-8
pubmed: 25870325
Liver Int. 2020 Jul;40(7):1578-1589
pubmed: 32304611
Mol Pharm. 2013 Feb 4;10(2):459-66
pubmed: 22738467
Hepatology. 2018 Apr;67(4):1560-1599
pubmed: 29405329
Lancet Gastroenterol Hepatol. 2016 Nov;1(3):196-206
pubmed: 28404092
AIDS Rev. 2016 Apr-Jun;18(2):59-68
pubmed: 27230467
J Gastroenterol. 2020 Sep;55(9):811-823
pubmed: 32666200
AIDS. 2012 Apr 24;26(7):867-75
pubmed: 22313955
J Hepatol. 2008 Oct;49(4):634-51
pubmed: 18715665
JAMA. 2018 May 01;319(17):1802-1813
pubmed: 29715359
J Infect Dis. 2017 Nov 16;216(suppl_8):S792-S796
pubmed: 29156043
BMC Nephrol. 2015 Jul 22;16:110
pubmed: 26199000
Lancet Infect Dis. 2008 Mar;8(3):167-78
pubmed: 18053766
J Gastroenterol Hepatol. 2019 Nov;34(11):2004-2010
pubmed: 31017689
J Hepatol. 2017 Aug;67(2):370-398
pubmed: 28427875
Liver Int. 2019 Oct;39(10):1868-1875
pubmed: 31136052